Should I Buy BLFS? BLFS 2026 Analysis

Should You Buy BioLife Solutions Inc (BLFS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

21.800

1 Day change

-3.45%

52 Week Range

29.620

Analysis Updated At

2026/01/28

Buy for a beginner long-term investor right now. BLFS is pulling back near support (~23.88) while the longer-term trend remains bullish (SMA_5 > SMA_20 > SMA_200), revenue is growing strongly (2025/Q3 +31% YoY), and Wall Street’s latest notable update is an Outperform with a raised target ($34). Despite weaker profitability this quarter, the setup favors starting a position at current levels rather than waiting for a perfect entry.

Technical Analysis

Price/Trend: BLFS is down -3.88% to 23.97 and trading below the pivot (25.01), sitting just above first support S1 (23.88). Longer-term trend remains constructive with bullish moving averages (SMA_5 > SMA_20 > SMA_200), suggesting the broader uptrend is intact despite today’s dip. Momentum: MACD histogram is positive (0.0453) but contracting, indicating bullish momentum is fading short-term. RSI_6 at 44.27 is neutral-to-slightly weak, consistent with a pullback rather than an overheated condition. Levels: Near-term resistance at 25.01 then 26.14; key supports at 23.88 then 23.18. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Open interest put/call ratio at 0.06 is extremely call-heavy (bullish positioning), but today’s options volume is essentially zero, so the sentiment read is based on positioning rather than active new trading. Volatility: Implied vol (30D) is very high at 86.4 vs historical vol 37.9, suggesting the market is pricing elevated uncertainty/range, even though the IV rank/percentile is moderate (IV rank ~21.9; IV percentile ~39.2).

Technical Summary

Sell

Buy

Positive Catalysts

and named BLFS a 2026 Top Pick, highlighting its role as a “pure play” in biopreservation and being embedded in pharma/biotech cell & gene therapy workflows.

Neutral/Negative Catalysts

Profitability deterioration in the latest quarter (net income and EPS down sharply YoY) despite revenue growth.
No fresh news catalysts in the last week to immediately reverse today’s weakness.
Short-term momentum is weakening (MACD positive but contracting; RSI below 50).

Financial Performance

Latest quarter (2025/Q3): Revenue rose to $28.07M (+31.21% YoY), showing strong top-line growth. However, profitability weakened materially: Net income fell to $0.62M (-136.47% YoY) and EPS dropped to $0.01 (-125% YoY). Gross margin slipped to 61.36% (-1.37% YoY). Overall: strong growth but inconsistent earnings performance in the most recent quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: The latest notable action (2026-01-05) is constructive—Northland raised its price target to $34 from $31 and maintained Outperform, calling BLFS a 2026 Top Pick. Wall Street pros: Positioned as a biopreservation “picks-and-shovels” play tied into cell & gene therapy programs from development through commercialization. Wall Street cons: Near-term earnings volatility/pressure (as seen in 2025/Q3) can weigh on the stock even with strong revenue growth. Influential trading check: Hedge funds and insiders are reported Neutral with no significant recent trends; no recent Congress trading data available.

6 Analyst Rating

Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 33.2 USD with a low forecast of 32 USD and a high forecast of 34 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 22.580

Low

Averages

33.2

High

Current: 22.580

Low

Averages

33.2

High

Northland

Outperform

maintain

$31 -> $34

AI Analysis

2026-01-05

Reason

Northland

Price Target

$31 -> $34

AI Analysis

2026-01-05

maintain

Outperform

Reason

Northland raised the firm's price target on BioLife Solutions to $34 from $31 and keeps an Outperform rating on the shares, which were also named a 2026 Top Pick. Following its re-establishment as a pure play and its control of the biopreservation layer in cell and gene therapy development, BioLife is "structurally locked into large pharma and biotech programs from initiation through commercialization," the analyst tells investors.

H.C. Wainwright

Buy

maintain

$30 -> $32

2025-08-08

Reason

H.C. Wainwright

Price Target

$30 -> $32

2025-08-08

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on BioLife Solutions to $32 from $30 and keeps a Buy rating on the shares following the Q2 beat.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BLFS

Unlock Now

BLFS Should I Buy

BLFS Should I Buy

Should You Buy BioLife Solutions Inc (BLFS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch